KRAS and lung carcinoma: We also compared the survival of lung cancer patients with co-occurrence of TP53, KRAS and EGFR mutation and CNVs to that of all other patients without each of these mutations/CNVs, respectively, and found similar results (Supplementary Figure 7A–C, Table S7A–C).